89 results on '"Wei, Andrew"'
Search Results
2. Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study
3. POSTER: AML-554 A Phase III, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine in Previously Untreated Patients With TP53-Mutant Acute Myeloid Leukemia
4. AML-554 A Phase III, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine in Previously Untreated Patients With TP53-Mutant Acute Myeloid Leukemia
5. POSTER: AML-370 Phase IB OMNIVERSE Trial: Safety and Tolerability of Oral Azacitidine (Oral-AZA) in Combination With Venetoclax (VEN) for Treatment of Acute Myeloid Leukemia (AML)
6. AML-370 Phase IB OMNIVERSE Trial: Safety and Tolerability of Oral Azacitidine (Oral-AZA) in Combination With Venetoclax (VEN) for Treatment of Acute Myeloid Leukemia (AML)
7. Updates in classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium of MDS (icMDS)
8. Acute myeloid leukaemia
9. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)
10. Azacitidine Monotherapy in Patients With Treatment-Naïve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis
11. Applying molecular measurable residual disease testing in acute myeloid leukaemia
12. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
13. Board of Directors’ Networks, Gender, and Firm Performance in a Male-Dominated Industry: Evidence from U.S. Banking
14. 3155 – GENOME WIDE CRISPR/CAS9 KNOCKOUT SCREEN IN VIVO IDENTIFY GATOR1 COMPONENTS AS TUMOR SUPPRESSORS IN Eµ-MYC LYMPHOMAGENESIS
15. Poster: AML-143 Trial in Progress: Phase Ib/II Study of Siremadlin in Combination With Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy (IC)
16. AML-143 Trial in Progress: Phase Ib/II Study of Siremadlin in Combination With Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy (IC)
17. Poster: MDS-476 Sabatolimab (MBG453) Combination Treatment Regimens for Patients With Higher-Risk Myelodysplastic Syndromes (HR-MDS): The Myelodysplastic Syndromes Studies in the STIMULUS Immuno-Myeloid Clinical Trial Program
18. Poster: AML-432 Overall Survival (OS) by IDH2 Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant-IDH2 Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial
19. Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses
20. AML-457 Oral Azacitidine (Oral-AZA) in Patients With Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial
21. MDS-476 Sabatolimab (MBG453) Combination Treatment Regimens for Patients With Higher-Risk Myelodysplastic Syndromes (HR-MDS): The Myelodysplastic Syndromes Studies in the STIMULUS Immuno-Myeloid Clinical Trial Program
22. Poster: AML-457 Oral Azacitidine (Oral-AZA) in Patients With Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial
23. Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies
24. Erratum to ‘Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system’ [Leukemia Research 112C (2022) 106748]
25. Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system
26. Cytosolic EZH2-IMPDH2 Complexes Regulate Melanoma Progression via GTP
27. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia
28. Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system
29. Sexism, household decisions, and the gender wage gap
30. Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades
31. Poster: MDS-420: Sabatolimab Plus Hypomethylating Agents (HMAs) in Patients with High-/Very High-risk Myelodysplastic Syndrome (HR/vHR-MDS) and Newly Diagnosed Acute Myeloid Leukemia (ND-AML): Subgroup Analysis of a Phase 1 Study
32. BCL-2 Inhibition in MDS
33. Poster: MDS-158: Updated Safety and Efficacy of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naïve, Higher-Risk Myelodysplastic Syndromes: Phase 1b Results
34. Poster: MDS-197: Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Higher-Risk (HR) Myelodysplastic Syndromes (MDS): The Phase 3, Randomized, ENHANCE Study
35. MDS-420: Sabatolimab Plus Hypomethylating Agents (HMAs) in Patients with High-/Very High-risk Myelodysplastic Syndrome (HR/vHR-MDS) and Newly Diagnosed Acute Myeloid Leukemia (ND-AML): Subgroup Analysis of a Phase 1 Study
36. AML-212: Treatment Free Remission (TFR) After Ceasing Venetoclax-Based Therapy in Responding Patients with Acute Myeloid Leukemia
37. MDS-158: Updated Safety and Efficacy of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naïve, Higher-Risk Myelodysplastic Syndromes: Phase 1b Results
38. MDS-404: Population Pharmacokinetics Modeling and Evaluation of Clinical Efficacy and Safety of Sabatolimab: Dose Selection and Dose-Response Analysis
39. Poster: MDS-404: Population Pharmacokinetics Modeling and Evaluation of Clinical Efficacy and Safety of Sabatolimab: Dose Selection and Dose-Response Analysis
40. MDS-197: Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Higher-Risk (HR) Myelodysplastic Syndromes (MDS): The Phase 3, Randomized, ENHANCE Study
41. Poster: AML-212: Treatment Free Remission (TFR) After Ceasing Venetoclax-Based Therapy in Responding Patients with Acute Myeloid Leukemia
42. Laboratory quality assessment of candidate gene panel testing for acute myeloid leukaemia: a joint ALLG / RCPAQAP initiative
43. Outcomes and health care utilization of older patients with acute myeloid leukemia
44. Impact of Subsequent Allogeneic Hematopoietic Stem Cell Transplant (HSCT) on Overall Survival (OS) Outcomes in the Quazar AML-001 Trial of Oral Azacitidine (CC-486) Maintenance Therapy for Patients with Acute Myeloid Leukemia (AML) in First Remission Who Were Not Eligible for HSCT at Study Entry
45. Tweets, Sexism, and the 2016 Presidential Election
46. Domestic Lending and the Pandemic: How Does Banks’ Exposure to COVID-19 Abroad Affect Their Lending in the United States?
47. Targeting MCL-1 in hematologic malignancies: Rationale and progress
48. AML-190: Anti-TIM-3 Antibody MBG453 in Combination with Hypomethylating Agents (HMAs) in Patients with High-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia: A Phase 1 Study
49. MDS-141: The Prognostic Impact of Cytogenetic Scores in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Venetoclax and Azacitidine in a Phase 1 Study
50. MDS-090: Semi-Mechanistic Model to Aid Clinical Understanding of Myelodysplastic Syndromes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.